A phase 2, randomized, double-blind, placebo-controlled study to evaluate a single intramuscular dose of motavizumab (MEDI-524), a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), for the outpatient treatment of children with RSV illness

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled study to evaluate a single intramuscular dose of motavizumab (MEDI-524), a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), for the outpatient treatment of children with RSV illness

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2008

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 13 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Feb 2008 The expected completion date for this trial is now 1 May 2009 according to ClinicalTrials.gov.
    • 14 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top